Melasolv induces melanosome autophagy to inhibit pigmentation in B16F1 cells

Hyun Jun Park1, Doo Sin Jo2, Hyunjung Choi3

  • 1School of Life Sciences, Kyungpook National University, Daegu, Republic of Korea.

Plos One
|September 17, 2020
PubMed

Insights

Melasolv treatment activates autophagy, a cellular degradation process, leading to reduced melanin in skin cells. This study clarifies the mechanism of Melasolv in depigmentation by promoting melanosome degradation.

Area of Science:

  • Cell Biology
  • Dermatology
  • Biochemistry

Background:

  • Melanosomes are key organelles for melanin production, but their degradation pathways are poorly understood.
  • Autophagy, involving autophagosomes and lysosomes, is crucial for cellular component degradation.
  • The role of autophagy in melanosome degradation and its link to depigmentation agents require further investigation.

Purpose of the Study:

  • To investigate the role of autophagy in melanosome degradation.
  • To determine the contribution of autophagy to the depigmenting effects of Melasolv.
  • To elucidate the mechanism by which Melasolv affects skin pigmentation.

Main Methods:

  • Utilized B16F1 melanoma cells for in vitro studies.
  • Assessed melanin content and autophagy activation.
  • Investigated the effects of Melasolv, bafilomycin A1 (autophagy inhibitor), and ATG5 (autophagy-related gene) on melanosome degradation and pigmentation.

Main Results:

  • Melasolv treatment suppressed melanin synthesis stimulated by α-melanocyte-stimulating hormone (α-MSH).
  • Melasolv activated autophagy in B16F1 cells.
  • Inhibition of autophagy by bafilomycin A1 or ATG5 significantly reduced Melasolv-induced melanosome degradation and depigmentation.

Conclusions:

  • Melasolv inhibits skin pigmentation by enhancing melanosome degradation.
  • Autophagy activation is a key mechanism underlying Melasolv's depigmenting effect.
  • This study clarifies the role of autophagy in the action of depigmenting agents.